aging

The Boston biotech closes a Series D round to advance ER-100, the first FDA-cleared therapy that uses partial epigenetic reprogramming to reverse cellular aging in humans.

A Chinese research team has shown that timed doses of 3'-deoxyadenosine can amplify circadian rhythms in one hypothalamic nucleus, roll back epigenetic age, and extend lifespan in aged male mice.

The US government's health research agency has funded the first large-scale clinical trials testing whether rapamycin, semaglutide, and other repurposed drugs can slow biological aging in healthy adults, with results expected within three years.

A Nature study identifies Parabacteroides goldsteinii as a driver of cognitive decline in aging mice and shows that stimulating the vagus nerve with GLP-1 receptor agonists restores memory to youthful levels.

Life Biosciences began the first human trial of a cellular rejuvenation therapy using partial epigenetic reprogramming in Q1 2026, while senolytic pilot data shows safety in Alzheimer's-risk patients.